Context Therapeutics Inc

Market Cap

$60M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.63-$0.92 (-59.34%)

Jul 15, 2026

52W High $3.3652W Low $0.55

Company Details

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to ...

Leadership

Martin A. LehrFounder

Co-Founder, President, CEO & Director

Jennifer Minai-Azary

CFO & Treasurer

Alex C. Levit Esq., J.D.

Chief Legal Officer & Corporate Secretary

Christopher Beck M.B.A.

Senior Vice President of Operations

Jeffrey Liebman

Associate Director of Accounting

Jennifer Dashnau M.B.A., Ph.D.

Senior Vice President of Technical Operations

Karen Chagin M.D.

Chief Medical Officer

IPO Date

Oct 20, 2021

Website

www.contexttherapeutics.com

Key Metrics TTM

Revenue

- YoY

Net Income

-$40M

EPS (Diluted)

Free Cash Flow

-$33M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee